Myeloma and Lymphoma Flashcards Preview

CLINICAL PATHOLOGY > Myeloma and Lymphoma > Flashcards

Flashcards in Myeloma and Lymphoma Deck (65)
Loading flashcards...
1
Q

Where does the process of B cell differentiation occur and what are the steps?

A

First stage in bone marrow (Ag independent stage)
Pro-B > Pre B > Immature B > Naïve B (outside of bone marrow)
Second stage is in the secondary lymphoid organs (antigen dependent) - mature naïve develop into proliferating blast cells

2
Q

What is significant about B cell differentiation in terms of diagnosing myeloma?

A

The plasma cells acquire different antigens at different points of differentiation, these antigens can be detected - each antigen CD? acts as a marker for the different intermediate cells in B cell differentiation

3
Q

How are immunoglobulins classified?

A

According to amino acid sequence in the constant region of the heavy chains - IgG, IgM, IgA, IgD, IgE
and the light chains - kappa or lambda

4
Q

What 5 major are normally identified in protein electrophoresis of serum, which is of interest in terms of myeloma?

A

1) Serum albumin
2) Alpha-1 globulin
3) Alpha-2 globulin
4) Beta globulins
5) Gamma globulins - called the M spike, this is of interest in myeloma, a normal M spike of polyclonal immunoglobulin which is shallow with no obvious peaks

5
Q

In myeloma, how would the gamma globulin peak appear on protein electrophoresis and why?

A

Rather than the shallow increase you would have one large peak reflecting the large scale production of monoclonal immunoglobulins - compared to the polyclonal production in a normal M spike

6
Q

If an M spike is identified on protein electrophoresis, what is the next step?

A

Immunofixation - enables the detection and identification of type of monoclonal Ig

7
Q

How is immunofixation carried out?

A
  • Serum or urine is placed on a gel and electric current is applied to separate out the proteins
  • Anti immunoglobulin antisera is added to each migration lane
  • If the immunoglobulin is present, a complex is precipitated
8
Q

What is myeloma?

A

An incurable malignant disorder of clonal plasma cells

9
Q

What is annual incidence of myeloma?

A

60-70 per million in the Uk

10
Q

What is the median age of presentation of myeloma?

A

70

11
Q

What ethnicity is at greater risk of developing myeloma?

A

Afro-carribean higher risk compared with Caucasians

12
Q

Myeloma is seen to be one of a spectrum of plasma cell dyscrasias - which 2 conditions lie before myeloma and which lies after in terms of severity?

A

1) MGUS - monoclonal gammopathy of undetermined significance
2) Asymptomatic/smouldering/indolent myeloma
3) Myeloma
4) Plasma cell leukaemia

13
Q

What is significant about MGUS?

A

Its is now thought that most cases of myeloma are preceded by MGUS

14
Q

Name 7 other plasma cell dyscrasias?

A

1) MGRS - monoclonal gammopathy of real significance
2) High-risk MGUS
3) Amyloidosis
4) Solitary plasmacytoma (with/without bone involvement)
5) Systemic AL amyloidosis
6) POEMS syndrome
7) Myeloma with adverse cellular features

15
Q

What is solitary plasmacytoma?

A

Get a discrete mass of abnormal plasma cells which can be deposited in bones such as femur or humerus but on further investigation no myeloma can be found in the marrow

16
Q

What is the IMWG diagnostic criteria for myeloma? 3

A

1) Clonal BM plasma cells >10% or biopsy proven bony or extramedullary plasmacytoma AND any one or more of
2) CRAB features
3) MDEs

17
Q

What are CRAB features?

A
Symptoms because of myeloma
C - hypercalcaemia
R - renal insufficiency
A - anaemia (plasma cell taking up too much room in the bone marrow)
B - bone lesions
18
Q

What are ‘myeloma defining events’?

A

Having a myeloma defining event is implication for asymptomatic/ smouldering myeloma cases - so more inclined to treat

19
Q

Name the 3 ‘myeloma defining events’ as defined by the IMWG diagnostic criteria?

A

1) >60% of plasma cells on BM biopsy
2) SFLC ratio (serum free light chain measurement) >100g/L provided the absolute levels of the involvement of LC is >100mg/L
3) >1 focal lesion on MRI measuring >5mm

20
Q

What percentage of myeloma patients have renal insufficiency at diagnosis?

A

20-25%

21
Q

What percentage of myeloma patients have renal insufficiency at some point during their disease course?

A

50%

22
Q

What percentage of myeloma patients will have persistent renal impairment despite therapy?

A

50%

23
Q

What percentage of myeloma patients will require RRT (renal replacement therapy)?

A

2-12%

24
Q

What is meant by external factors affecting the kidney in myeloma?

A

Factors separate to the myeloma which are making the kidneys worse which we can do something about

25
Q

Name the 9 external factors affecting the kidney in myeloma?

A

1) Renal venous thrombosis
2) Bisphosphonates (used to treat hypercalcaemia which is usually due to myeloma)
3) ACE inhibitors
4) Type 1 cryoglobulinaemia
5) Dehydration
6) NSAIDs
7) CT contrast
8) Hyper viscosity - extra proteins produced by neoplastic cells make blood very viscous
9) Hypercalcaemia

26
Q

What is the immediate management for AKI with suspected myeloma, why should it be treated immediately?

A

It is a medical emergency - ‘time = nephrons’

Immediate treatment = steroids

27
Q

Following the administration of steroids what are the next 4 steps in the management of AKI with suspected myeloma?

A

1) Blood film
2) Electrophoresis
3) Immunofixation
4) Bone marrow biopsy with flow cytometry

28
Q

What is intensive therapy used to manage myeloma?

A

4 cycles of chemo with VCD
Patient given GCSF to stimulate production of stem cells and increase levels in the peripheral blood
Patients stem cells are harvested from peripheral blood and frozen
Patients are given another large dose of chemotherapy
Patients serum then auto-replaced to help the patient get back to normal

29
Q

In which patients is intensive therapy for myeloma used?

A

Those who are younger and fitter

30
Q

What is the average number of months before remission after intensive therapy?

A

18 months

31
Q

What is the treatment between intensive therapy and remission?

A

Cycles of RD chemo

32
Q

Can bone marrow transplantation be used in managing myeloma?

A

Sometimes - but is associated with high mortality and remission still occurs

33
Q

Name 3 newer agents to treat myeloma?

A

1) Daratumumab (antiCD138)
2) Carfilzomib (proteasome inhibitor)
3) Ixazomib (proteasome inhibitor)
Monoclonal Ab

34
Q

What is non-intensive therapy used to treat myeloma, which patients is this used in?

A

Used in a lot of patients in their 60s/70s who have lots of other comorbidities to keep the myeloma under control and keep them out of hospital
5 rounds of chemo - CDTa
4 more rounds of chemo - VCD
RD chemo until disease progresses

35
Q

What is the immediate therapy given in suspected myeloma?

A

Steroids

36
Q

What are the 3 simple measures its important to follow in the treatment of myeloma?

A

1) Hydration
2) Avoid nephrotoxics
3) Chemotherapy (attenuated dosing)

37
Q

What are the 3 IMWG diagnostic criteria for MGUS?

A

1) Serum M protein

38
Q

Which sex is MGUS greater in?

A

Males

39
Q

How is MGUS likely to present on bloods?

A

Hb, and Ca2+ normal
Creatinine maybe slightly raised
One type of IgG raised eg. IgG kappa

40
Q

What is the prevalence of MGUS?

A
  1. 2% people more than 50
  2. 3% people more than 70
  3. 9% people more than 80
41
Q

What is the risk of progression from MGUS to myeloma?

A

Majority progress to myeloma

42
Q

What 3 other conditions do people with MGUS also progress to?

A

1) Waldenstrom’s macroglobulinaemia
2) Primary AL amyloidosis
3) Lymphoproliferative disorders

43
Q

What 3 things increase the risk of progression from MGUS?

A

1) High vs low M protein (15g/L)
2) IgA/IgM vs IgG PP
3) Abnormal SFLC ratio vs normal

44
Q

What is AL amyloidosis?

A

Amyloid light chain amyloidosis
Have a population of neoplastic plasma cells which secrete abnormal protein, these light chain fragments misfold and self aggregate to form beta-pleated fibrils which get deposited in different organs eg. kidneys, liver and heart

45
Q

What is the incidence of AL amyloidosis?

A

600 new cases per year

46
Q

What is a common presentation of AL amyloidosis?

A

Nephrotic range proteinuria - mainly albumin, small monoclonal light chain involvement

47
Q

In addition to nephrotic range proteinuria, what are the 3 other possible clinical features of AL amyloidosis?

A

1) Cardiac and liver involvement - 30%
2) Peripheral neuropathy - 10%
3) ESRF (end stage renal failure) - 40%

48
Q

When a patient presents with a neck mass, what are the 3 possible malignant causes and the 5 possible non-malignant causes?

A
Malignant:
1) Lymphoma
2) Chronic lymphocytic leukaemia
3) Metastatic cancer of the lung, breast and cervix 
Non malignant:
1) Infective (bacterial , viral, mycobacterial)
2) Inflammatory (sarcoidosis)
3) Lipoma
4) Fibroma
5) Haemangioma
49
Q

What are the important further investigations when a patient presents with a neck mass (7 bloods, 3 imaging)?

A

Bloods: U&Es, FBC, LFT, Ca2+, LDL (if raised more suspicious of high grade lymphoma), Igs and protein electrophoresis
Imaging: CXR, US of neck lump, fine needle aspirate and/or core needle biopsy

50
Q

What blood result would make you more suspicious of a high grade lymphoma in a patient presenting with a neck mass?

A

Raised LDL

51
Q

What are the broad categories of lymphoma?

A

Hodgkin and non Hodgkin

52
Q

What is follicular lymphoma?

A

Neoplastic disorder of lymphoid tissue

Type of non Hodgkin lymphoma characterised by slowly enlarging lymph nodes

53
Q

Follicular lymphoma accounts for what percentage of all non Hodgkin lymphomas?

A

15%

54
Q

How is the incidence of follicular lymphoma affected by age and sex?

A

No difference between sexes

Incidence in creases with age

55
Q

What is the characteristic chromosomal change in follicular lymphoma, what effect does this have?

A

Translocation - t(14:18)
Brings the bcl2 protooncogene under the influence of the Ig heavy chain gene leading to overexpression of the bcl-2 protein, this confers a survival advantage to the neoplastic lymphoid cells be inhibiting apoptosis

56
Q

What is the median survival and overall 5 year survival in follicular lymphoma?

A

Median survival = 8-10 years

Five year overall survival = 72-77%

57
Q

Which index can be used in assessing prognosis in follicular lymphoma, what 5 parameters does it use?

A

Follicular International Prognostic Index (FLIPI)

1) Age >60 years
2) Ann harbor stage III or IV
3) LDL above the limit of normal at diagnosis
4) Hb

58
Q

Using the FLIPI (follicular internation prognostic index) how does score affect prognosis?

A

If a patient has 4 or more prognostic factors than the 10 year survival rate it 36% compared with 71% for those with one or none

59
Q

What characterises Hodgkins lymphoma?

A

The presence of Hodgkin-Reed Sternberg (HRS) cells within a cellular infiltrate of non malignant inflammatory cells

60
Q

How are HRS (Hodgkin Reed Sternberg) cells neoplastic?

A

Fail to express Ig and evade apoptosis through a variety of methods eg. Activation of NKkB, incorporation of EBV and latent membrane proteins (LMP1 and LMP2)

61
Q

What are the 4 classical classifications of lymphoma, what is it based on?

A
Based on appearance of biopsy
Nodular lymphocyte is predominant 
Classifications:
1) Nodular sclerosis
2) Mixed cellularity
3) Mixed lymphocyte-rich
4) Lymphocyte depleted
62
Q

How is lymphoma managed?

A

Chemo and radiotherapy with doses/number of courses depending on stage

63
Q

Is lymphoma curable?

A

Yes a lot of people are cured

64
Q

What is the percentage 5 year survival for lymphoma?

A

85%

65
Q

The long term effects of lymphoma therapy are significant, name 4 significant long term effects?

A

1) Increased mortality still seen at >20 years post therapy
2) Pulmonary toxicity
3) CV disease
4) Secondary malignancies

Decks in CLINICAL PATHOLOGY Class (56):